BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan P, Song J, Wang F, Zhu G, Chen B. Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma. Invest New Drugs 2022;40:1125-32. [PMID: 35793038 DOI: 10.1007/s10637-022-01257-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Guo P, Pi X, Gao F, Li Q, Li D, Feng W, Cao W. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study. Front Oncol 2022;12:945915. [DOI: 10.3389/fonc.2022.945915] [Reference Citation Analysis]
2 Marcus R, Christopher W, Keller J, Nassoiy S, Chang SC, Goldfarb M, Wolf R, Jutric Z. Systemic Therapy Is Associated with Improved Oncologic Outcomes in Resectable Stage II/III Intrahepatic Cholangiocarcinoma: An Examination of the National Cancer Database over the Past Decade. Cancers (Basel) 2022;14:4320. [PMID: 36077855 DOI: 10.3390/cancers14174320] [Reference Citation Analysis]